Israel-based Respinova has won the second grant offered by Chiesi Spain and Richi Entrepreneurs to promote an innovative project that directly impacts treatment and quality of life of patients with chronic obstructive pulmonary disease (COPD).
As a result, two members of Respinova will participate in Richi Entrepreneurs’ Boston Immersion Program.
Respinova’s PulseHaler is a non-invasive technology that aims to treat the core pathophysiology of COPD.The technology has been clinically demonstrated to improve exercise capacity, lung function, and quality of life for COPD patients.
In a statement, Cliff Ansel, CEO of Respinova, said the “scholarship to the Boston Innovation Program will allow us to experience one of the leading health-tech ecosystems first hand.”
Giuseppe Chiericatti, general manager of Chiesi Spain, said the search for effective and innovative solutions for the treatment of respiratory diseases is one of Chiesi’s main commitments.
Chiesi Spain is part of Chiesi Farmaceutici, a pharmaceutical company based in Parma, Italy, created more than 80 years ago. Richi Entrepreneurs is a Richi Foundation initiative whose mission is to boost life sciences start-ups.
